


MicroPort Scientific Corporation

2024 Interim Results

30 August 2024





Contents



Company Highlights

Business Review

Financial Review

Appendix Financial Statements

Strong Results Underpinned by Strategic Focus and Transformation Efforts

Transformation Underway

Reshaping our business with full P&L responsibility and to create shareholder value



Strategic Priorities	1H2024 Progress
Category Leadership	Revenue \$558.7 mn ▲17.0% ^{YOY} Leading market share in domestic for major segments
Meaningful Innovation	31 NMPA 11 CE Mark 4 FDA approvals YTD 4 Green Paths YTD, 34 in total No.1 in industry for 9 consecutive years Firesorb® obtained NMPA approval
Global Expansion	Going-abroad business revenue ▲44.0% ^{YOY} ▲56.3% ^{YOY} ▲65.0% ^{YOY} ▲87.0% ^{YOY} ▲29.2% ^{YOY} ▲293.2% ^{YOY}
Unlock Efficiency	Total Operating Exp. ratio significantly dropped from 94% to 64% ^{YOY} R&D Exp. ratio substantially reduced from 39% to 21% ^{YOY}
Narrowed Strategic Focus	Divestment of non-core business & asset Shut down R&D projects at early stages based on evaluation






Non-HKFRS Net Loss Substantially Reduced by ▼63.1%^{YOY}

Note: 1. revenue growth rate adjusted to exclude foreign exchange impact, due to appreciation or depreciation of US\$ against functional currencies.

Positive Momentum Across Business Segments


Rapid Revenue Growth

Segment	Revenue	YoY Changes	China Revenue YoY Changes
 Orthopedics	\$126.3mn	9.0%	32.5%
 CRM	\$113.4mn	5.6%	61.5%


Segment	Revenue	YoY Changes	Going-abroad Revenue YoY Changes
 Cardiovascular	\$93.3mn	13.4%	56.3%
 Endovascular	\$110.4mn	26.3%	65.0%
 Neurovascular	\$57.1mn	36.5%	87.0%
 Structural Heart	\$31.1mn	26.7%	29.2%
 Surgical Robots	\$10.0mn	117.0%	293.2%

Diversified Business

Revenue by Segment



Revenue by Geography






Note: 1. revenue growth rate adjusted to exclude foreign exchange impact, due to appreciation or depreciation of US\$ against functional currencies.

Substantially Expense Reduced & Cost Effectiveness Increased

Improved Operating Efficiency

Strict Cost Control Across Key Items

Non-HKFRS Adjusted Net Loss Substantially Narrowed



Note: 1. revenue growth rate adjusted to exclude foreign exchange impact, due to appreciation or depreciation of US\$ against functional currencies.



Contents



Company Highlights

Business Review


Financial Review

Appendix Financial Statements

Cardiovascular Business: Net Profit Substantially Increased by 279.4%^{YOY}

Most Complete Product Pipeline In Coronary Field

Key Financials



Business Highlights



China

1H24 revenue up 4.4%^{YOY}, among which the DES products growth are higher than the market level, further enhanced its position of No.1 market share

Hospital coverage expanding: DES portfolio has accumulatively entered 3,500+ hospitals, achieving stable growth in market share

The new generation of bioresorbable scaffold Firesorb[®] obtained NMPA approval
Atherectomy Wire obtained NMPA approval



Non-China

1H24 revenue up 56.3%^{YOY}, strong growth achieved in EMEA (up 107.9%^{YOY}) Asia-Pacific (excluding China, up 43.4%^{YOY}) and Latin America (up 6.1%^{YOY})

Extensive sales network: DES sales cover over 80+ countries and regions

Diversified & flexible product portfolio to maintain a leading market position

Complete & Diversified Product Pipeline

Device Type	Diagnostic Device				
		Argusclarity[®] Insight-100 Optical Coherence Tomography System NMPA approval		Argusclarity[®] Insight-100h Optical Coherence Tomography System NMPA approval	
		Soul-Man[™] Digital Subtracting Angiography System NMPA approval		Decypher[®] Intravascular Ultrasound Imaging System Upcoming approval by NMPA	
Therapeutic Device	Active		Integrated Coronary Intravascular Lithotripsy System Upcoming approval by NMPA		Integrated Coronary Transluminal Rotational Atherectomy System Upcoming approval by NMPA
			Firebird2[®] Rapamycin-Eluting Coronary Cocirc Stent System NMPA approval		Firehawk[™] Rapamycin Target Eluting Coronary Stent System NMPA approval
			Firesorb[®] Bioresorbable Rapamycin Eluting Coronary Scaffold System NMPA approval		Coronary Sirolimus Eluting Balloon Catheter Upcoming approval by NMPA
	Non-active		Pioneer[™] PTCA Balloon Catheter NMPA approval		Firefighter[™] PTCA Balloon Catheter NMPA approval
			AncherV[®] Exchange Device NMPA approval		Coronary Scoring Balloon Catheter Upcoming approval by NMPA
			Interline[™] Guiding Catheter NMPA approval		Bilumos[®] Dual-lumen Catheter NMPA approval

Note: 1. revenue growth rate adjusted to exclude foreign exchange impact, due to appreciation or depreciation of US\$ against functional currencies.

Orthopedics Business Positive EBITDA Achieved

Revenue Increased By 9.0% YoY

Non-China Business



China Business

Business Highlights

■ Products newly approved for marketing


Note: 1. revenue growth rate adjusted to exclude foreign exchange impact, due to appreciation or depreciation of US\$ against functional currencies.

CRM Business: EBITDA significantly improved

Revenue Increased By 5.6%^{YoY}



Non-China Business



Business Highlights

1H24 revenue up 1.3%^{YoY}

upstream parts supply problem has been comprehensively solved

Expediting market entry:

CE Approval for TALENTIA and ENERGY defibrillators, cardiac resynchronization therapy

defibrillators (CRT-Ds), and XFine™ leads

TALENTIA ICDs and CRT-Ds approved in Australia

EDIS and GALI defibrillator systems approved in Cyprus


1st commercial implantation :

High Voltage

Low Voltage



China Business



Business Highlights

1H24 revenue up 61.5%^{YoY}, with revenue of pacemakers up 50.8%^{YoY}; revenue of leads up 64.6%

Accelerated market penetration driven by continuous bids winning in VBP tenders, further consolidate Top 1 market position among domestic pacemakers

GPM improved by 22 pts led by proactive dynamic adjustment of product mix and continuous efforts in reduction of costs

Further enriched product portfolio strengthens competitive position: NMPA approval obtained for

imported 1.5T/3T full-body MRI compatible pacemaker, bridged the intergenerational divide with MNCs, offering premium choices to Chinese patients


the domestic 1.5T/3T full-body MRI compatible pacemaker

■ Products newly approved for marketing

Note: 1. revenue growth rate adjusted to exclude foreign exchange impact, due to appreciation or depreciation of US\$ against functional currencies.

Endovascular Business

Key Financials



Business Highlights



China

1H24 revenue up 23.6%^{YOY}, key products recorded steady growth, accelerated hospital entry of new products

Innovative products approved in recent years accelerate market penetration: Castor[®], -in-class thoracic branch stent-graft system, covered **1,100+** hospitals, Minos[®] covered **nearly 900** hospitals, Reewarm[®] PTX covered **1000+** hospitals, Fontus[®] covered **200+** hospitals; Talos[®] covered **nearly 300** hospitals since approval

Further enriched product pipeline: L-REBOA[®], Vewatch[®], Vepack[®], Vflower[®], ReeAmber[®] were approved for marketing by the NMPA



Non-China

1H24 revenue up 65.0%^{YOY}, core products accelerate the development and layout of overseas markets

Rapid progressing global launch of core products: Castor[®] entered into **19** countries, Minos[®] entered into **21** countries, Hercules[®] Low Profile entered into **22** countries

Swiftly advancing overseas sales channel: newly developed **3** countries, innovative products covered **34** markets accumulatively, across EU, Latin America and Southeast Asia

Achieved significant progress for R&D projects: **8** new certificates were obtained in overseas markets; Cratos[®] received the EU Customized Certificate


	Product	Pre-clinical	Clinical	Registration
Aortic Intervention	L-REBOA [®] Aortic Occlusion Balloon Catheter		Obtained NMPA approval	
	Cratos [®] Branched Aortic Stent-Graft System		Submitted for NMPA review	
	Aegis [®] II Abdominal Aortic Stent-Graft System		Awarded the EU Customized Certificate	
	Hector [®] Multi-branched Aortic Stent-Graft System		Conducting pre-market clinical trial	
	Aortic Tear Flow-Restriction Stent		Conducting FIM clinical trial	
Peripheral Venous Intervention	Vflower [®] Venous Stent System		Obtained NMPA approval	
	Vewatch [®] Vena Cava Filter		Obtained NMPA approval	
	Vepack [®] Filter Retriever		Obtained NMPA approval	
	Fishhawk [®] Mechanical Thrombectomy Catheter		Completed pre-market clinical trial	
	ReeAmber [®] Balloon Dilation Catheter		Obtained NMPA approval	
Peripheral Arterial Intervention	Ryfle [®] Fibered Embolization Coil		Submitted for NMPA review	
	Below-The Knee Drug Coated Balloon Catheter		Conducting pre-market clinical trial	
Oncological Intervention	HepaFlow [®] TIPS Stent Graft System		Completed pre-market clinical trial	
	Transjugular Liver Access Set		Submitted for NMPA review	
	Polyvinyl Alcohol (PVA) Embolic Microspheres		Conducting pre-market clinical trial	

 Product admitted to NMPA Green Path

Note: 1. revenue growth rate adjusted to exclude foreign exchange impact, due to appreciation or depreciation of US\$ against functional currencies.

Neurovascular Business

Key Financials



Business Highlights

1H24 revenue up 33.8%^{YOY}, key products recorded steady growth, accelerated hospital entry of new products

Coverage of high-quality hospitals accelerates market penetration: approximately 300 hospitals have been newly covered, with a total coverage of about 3300 hospitals, accumulated support for approximately 190,000 neuro-interventional surgeries



China



Non-China

Product Pre-clinical Clinical Registration

Hemorrhagic Stroke

CAS

AIS



Access Product



Product admitted to NMPA Green Path

Note: 1. revenue growth rate adjusted to exclude foreign exchange impact, due to appreciation or depreciation of US\$ against functional currencies.

Structural Heart Business



Note: 1. revenue growth rate adjusted to exclude foreign exchange impact, due to appreciation or depreciation of US\$ against functional currencies.

Surgical Robot Business

Key Financials



Business Highlights

1H24 revenue up 65.3%^{YOY}, recorded robust sales growth and rapid pace of commercialization

Leading position among domestic brands



China

Toumai®	R-ONE®
7 units of new commercial installation Overall commercial installation base reached 20 units to date, No.1 among domestic brands	2 units of commercialized installation following the NMPA approval in Dec 23

1H24 revenue up 293.2%^{YOY}, overseas markets reached a milestone in commercialization, **Toumai® obtained CE Mark**

Ambitious Overseas Penetration



Non-China

Toumai®	SkyWalker™
Successfully completed the first 2 commercial installations with revenue breakthrough	Sales unit doubled YoY on the leverage of synergies with Orthopedics Business
Received over 10 units of overseas orders up to date	Accumulatively received nearly 30 overseas orders up to date
Conducted ~100 clinical operations in overseas hospitals up to date	Expanded to cover 20+ countries across 5 continents
Created over 20 records of 1st remote surgery in China and globally	

	Product	Pre-clinical	Clinical	Registration
Laparoscopic	Toumai® Laparoscopic Surgical Robot			Obtained NMPA approval Obtained CE marking
	Toumai® Remote Laparoscopic Surgical Robot		Conducting Clinical trial/ Clinical Evaluation	
	Toumai® Single-arm Laparoscopic Surgical Robot		Submitted for NMPA review	
Orthopedic	DFVision® 3D Electronic Laparoscope			Obtained NMPA approval Obtained CE marking
	SkyWalker™ Orthopedic Surgical Robot			Obtained NMPA approval Obtained CE& FDA& ANVISA& TGA & CDSCO approval
Natural Orifice	Trans-bronchial Surgical Robot		Conducting Clinical trial/ Clinical Evaluation	
Panvascular	R-ONE® Panvascular Surgical Robot			Obtained NMPA approval
Percutaneous	® Mona Lisa Robotic Transperineal Prostate Biopsy System			Obtained NMPA approval

Product admitted to NMPA Green Path

Note: 1. revenue growth rate adjusted to exclude foreign exchange impact, due to appreciation or depreciation of US\$ against functional currencies.

Contents



Company Highlights

Business Review


Financial Review

Appendix Financial Statements

Consolidated Financial Performance

Revenue

USD: million




Gross Profit Margin




Operating Expenses

USD: million



Non-HKFRS Adjusted Net Loss & Total Net Loss

USD: million




■ Amount ● % of sales

Note: revenue growth rate adjusted to exclude foreign exchange impact, due to appreciation or depreciation of US\$ against functional currencies

Operating Expenses

R&D Expenses

USD: million




R&D expenses decreased by 38.6%^{YOY}

- ♦ Due to the proactive cost control and resource focus measures to prioritize and focus on core projects and improve R&D efficiency

Administrative Expenses

USD: million




Administrative expenses decreased by 12.6%^{YOY}

- ♦ Due to the Group's effective cost control and scale of operations


Sales & Marketing Expenses

USD: million



Sales & marketing expenses decreased by 8.0%^{YOY}

- ♦ Due to efforts to strengthen the synergy and interconnectivity between overseas and domestic sales platforms.



Consolidated Income Statement

USD'000	2024 1H	2023 1H	Var.
Revenue	558,702	482,605	15.8%
Cost of sales	(228,122)	(194,189)	17.5%
Gross profit	330,580	288,416	14.6%
Other net income	(68)	17,039	-100.4%
Research and development costs	(115,033)	(187,334)	-38.6%
Distribution cost	(156,150)	(169,800)	-8.0%
Administrative expenses	(83,785)	(95,890)	-12.6%
Other operating costs	(12,348)	(12,374)	-0.2%
Loss from operations	(36,804)	(159,943)	-77.0%
Finance cost	(48,416)	(37,256)	30.0%
Gain on disposal of subsidiaries	6,922	2,845	143.3%
Gain on deemed disposal of interest in equity-accounted investees	-	5,437	-100.0%
Share of profits less losses of equity-accounted investees	(8,146)	(17,258)	-52.8%
Loss before taxation	(86,444)	(206,175)	-58.1%
Income tax	(20,230)	(13,746)	47.2%
Loss for the period	(106,674)	(219,921)	-51.5%
Attributable to: Equity shareholders of the Company	(96,830)	(162,618)	-40.5%



